Browsing Category
Case Studies
Novartis reports zero impact of Cosentyx on moderate to severe plaque psoriasis
Novartis declared additional results from the SCULPTURE study marking that two thirds of moderate to severe plaque psoriasis patients treated with Cosentyx exhibited zero impact of skin…
Read More...
Read More...
Merck overturns APECS Study assessing Verubecestat (MK-8931) for Prodromal Alzheimer’s Disease
Merck declared that it will rescind protocol 019 also termed as the APECS study assessing verubecestat (MK-8931), an investigational small molecule inhibitor of the beta-site amyloid…
Read More...
Read More...